Innovative Nanocarrier Strategies for Enhanced Docetaxel Delivery in Cancer Therapy
Abstract
Docetaxel (DTX) and several other taxanes are one of the most important class of anticancer chemotherapeutic agent. DTX commercially marketed as Taxotere® has higher clinical significance amongst other taxanes owing it a wide range of clinical applications. Although its broad range of applications and wide commercial use, its clinical use limited due to associated undesired side toxicity. Recent developments in nanotechnology has emerged with novel ways to overcome the limitations of DTX. Numerous nanocarrier system offer enhanced efficacy of DTX by utilizing EPR effect, tumor vascular hyperpermeability, reduced lymphatic drainage and raised interstitial fluid pressure in tumor cells. Furthermore, these systems can be actively transported via targeting over expressed receptors in tumor cells or via targeting tumor endothelium. This review covers a range nanocarrier based formulations of DTX used for in-vitro and in-vivo evaluation for several types of cancer. Although nanoformulations such as polymeric nanoparticles, lipidic nanoparticles or inorganic nanoparticles significantly enhance the solubility, efficacy and bio-distribution of DTX, important obstacles of nanoformulations such as quality control, stability (physico-chemical and physiological), industrial-scale manufacturing and technology, in-vivo fate (metabolism, excretion, and chronic toxicity) still remain a concern. Numerous supporting data and regulatory guidelines should be established regarding these concerns to make DTX nanoformulations applicable widespread clinically.
Keywords: Docetaxel; Nanocarriers; EPR effect; Cancer therapeutics; Cancer drug resistance.
Keywords:
Docetaxel , Nanocarriers, EPR effect, Cancer therapeutics, Cancer drug resistance.DOI
https://doi.org/10.22270/jddt.v16i3.7601References
1. Tan Q, Liu X, Fu X, Li Q, Dou J, Zhai G. Current development in nanoformulations of docetaxel. Expert Opin Drug Deliv. 2012 Aug;98:975-90. https://doi.org/10.1517/17425247.2012.696606 PMid:22703284
2. Wang YF, Shi QW, Dong M, Kiyota H, Gu YC, Cong B. Natural Taxanes: Developments Since 1828. Chem Rev. 2011 Dec 14;11112:7652-709. https://doi.org/10.1021/cr100147u PMid:21970550
3. Clarke SJ, Rivory LP. Clinical Pharmacokinetics of Docetaxel. Clin Pharmacokinet. 1999; https://doi.org/10.2165/00003088-199936020-00002 PMid:10092957
4. Zhao P, Astruc D. Docetaxel Nanotechnology in Anticancer Therapy. ChemMedChem. 2012 Jun;76:952-72. https://doi.org/10.1002/cmdc.201200052 PMid:22517723
5. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogs and their antimitotic activity. J Med Chem. 1991 Mar;343:992-8. https://doi.org/10.1021/jm00107a017 PMid:1672159
6. Nicolaou KC, Guy RK, Potier P. Taxoids: New Weapons against Cancer. Sci Am. 1996 Jun;2746:94-8. https://doi.org/10.1038/scientificamerican0696-94 PMid:8643952
7. Guenard D, Gueritte-Voegelein F, Potier P. Taxol and taxotere: discovery, chemistry, and structure-activity relationships. Acc Chem Res. 1993 Apr 1;264:160-7. https://doi.org/10.1021/ar00028a005
8. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in -tubulin: A model based on electron crystallographic density. PNAS. 2001 Apr;989:5312-6. https://doi.org/10.1073/pnas.051309398 PMid:11309480 PMCid:PMC33206
9. Yvon AMC, Wadsworth P, Jordan MA. Taxol Suppresses Dynamics of Individual Microtubules in Living Human Tumor Cells. Kirschner MW, editor. Mol Biol Cell. 1999 Apr;104:947-59. https://doi.org/10.1091/mbc.10.4.947 PMid:10198049 PMCid:PMC25218
10. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999 Jan;101:33-8. https://doi.org/10.1023/A:1008354600497 PMid:10076719
11. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1995 Feb;132:314-22. https://doi.org/10.1200/JCO.1995.13.2.314 PMid:7844592
12. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. Journalof Clin Oncol. 1995 Mar;133:645-51. https://doi.org/10.1200/JCO.1995.13.3.645 PMid:7884425
13. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer-an updated overview. Eur J Cancer. 1997 Nov;3313:2167-70. https://doi.org/10.1016/S0959-8049(97)00363-8 PMid:9470802
14. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, et al. Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open. 2018;32:e000285. https://doi.org/10.1136/esmoopen-2017-000285 PMid:29464109 PMCid:PMC5812392
15. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023 Jul;104:1367-401. https://doi.org/10.1016/j.gendis.2022.02.007 PMid:37397557 PMCid:PMC10310991
16. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;731:17-48. https://doi.org/10.3322/caac.21763 PMid:36633525 PMCid:PMC12559696
17. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021 Jul;9:1-10. https://doi.org/10.1177/20503121211034366 PMid:34408877 PMCid:PMC8366192
18. Basak D, Arrighi S, Darwiche Y, Deb S. Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile. Life. 2021 Dec 29;121:48. https://doi.org/10.3390/life12010048 PMid:35054441 PMCid:PMC8777973
19. Imran M, Saleem S, Chaudhuri A, Ali J, Baboota S. Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer. J Drug Deliv Sci Technol. 2020 Dec;60:101959. https://doi.org/10.1016/j.jddst.2020.101959
20. Sohail MF, Rehman M, Sarwar HS, Naveed S, Qureshi OS, Bukhari NI, et al. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomedicine. 2018 Jun;Volume 13:3145-61. https://doi.org/10.2147/IJN.S164518 PMid:29922053 PMCid:PMC5997133
21. Valicherla GR, Dave KM, Syed AA, Riyazuddin M, Gupta AP, Singh A, et al. Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity. Sci Rep. 2016 May 31;61:26895. https://doi.org/10.1038/srep26895 PMid:27241877 PMCid:PMC4886259
22. Alqosaibi AI. Nanocarriers for anticancer drugs: Challenges and perspectives. Saudi J Biol Sci. 2022 Jun;296:103298. https://doi.org/10.1016/j.sjbs.2022.103298 PMid:35645591 PMCid:PMC9130109
23. Edis Z, Wang J, Waqas MK, Ijaz M, Ijaz M. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. Int J Nanomedicine. 2021 Feb;Volume 16:1313-30. https://doi.org/10.2147/IJN.S289443 PMid:33628022 PMCid:PMC7898224
24. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules. 2020 May 8;259:2193. https://doi.org/10.3390/molecules25092193 PMid:32397080 PMCid:PMC7248934
25. Makwana V, Karanjia J, Haselhorst T, Anoopkumar-Dukie S, Rudrawar S. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. Int J Pharm. 2021 Jan;593:120117. https://doi.org/10.1016/j.ijpharm.2020.120117 PMid:33259901
26. Niu G, Cogburn B, Hughes J. Preparation and Characterization of Doxorubicin Liposomes. In: Grobmyer SR, Moudgil BM, editors. Cancer Nanotechnology [Internet]. Totowa, NJ: Humana Press; 2010 [cited 2024 Jun 10]. p. 211-9. (Methods in Molecular Biology; vol. 624). Available from: http://link.springer.com/10.1007/978-1-60761-609-2_14 https://doi.org/10.1007/978-1-60761-609-2_14 PMid:20217598
27. Wu C, Gao Y, Liu Y, Xu X. Pure paclitaxel nanoparticles: preparation, characterization, and antitumor effect for human liver cancer SMMC-7721 cells. Int J Nanomedicine. 2018 Oct;Volume 13:6189-98. https://doi.org/10.2147/IJN.S169209 PMid:30349243 PMCid:PMC6188176
28. Gade JV, Prashant Sharma P, Jain B, Rawat R. Synthesis and characterization of paclitaxel nanoparticles for drug delivery. Mater Today Proc. 2022;51:445-50. https://doi.org/10.1016/j.matpr.2021.05.573
29. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther. 2005 Oct 1;410:1495-504. https://doi.org/10.1158/1535-7163.MCT-05-0130 PMid:16227398
30. Azarenko O, Smiyun G, Mah J, Wilson L, Jordan MA. Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells. Mol Cancer Ther. 2014 Aug 1;138:2092-103. https://doi.org/10.1158/1535-7163.MCT-14-0265 PMid:24980947
31. Hernández-Vargas H, Palacios J, Moreno-Bueno G. Telling Cells How to Die: Docetaxel Therapy in Cancer Cell Lines. Cell Cycle. 2007 Apr;67:780-3. https://doi.org/10.4161/cc.6.7.4050 PMid:17377494
32. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003 Oct;295:407-15. https://doi.org/10.1016/S0305-7372(03)00097-5 PMid:12972359
33. Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, Heys SD, et al. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res. 2004 Aug 5;65:R601. https://doi.org/10.1186/bcr918 PMid:15318941 PMCid:PMC549179
34. Lee SW, Yun MH, Jeong SW, In CH, Kim JY, Seo MH, et al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PMTM using polymer-based delivery system. J Controlled Release. 2011 Oct;1552:262-71. https://doi.org/10.1016/j.jconrel.2011.06.012 PMid:21704664
35. Zhang H, Dou J, Zhai Y, Liu A, Zhai G. Advances in the formulations of non-injection administration of docetaxel. J Drug Target. 2014 Feb;222:87-94. https://doi.org/10.3109/1061186X.2013.839686 PMid:24098909
36. Sonali, Singh RP, Singh N, Sharma G, Vijayakumar MR, Koch B, et al. Transferrin liposomes of docetaxel for brain-targeted cancer applications: formulation and brain theranostics. Drug Deliv. 2016 May 3;234:1261-71. https://doi.org/10.3109/10717544.2016.1162878 PMid:26961144
37. Hu X, Yang F, Liao Y, Li L, Zhao G, Zhang L. Docetaxel-Loaded Cholesterol-PEG Co-Modified Poly (n-Butyl) Cyanoacrylate Nanoparticles for Antitumor Drug Pulmonary Delivery: Preparation, Characterization, and in vivo Evaluation. Int J Nanomedicine. 2020 Jul;Volume 15:5361-76. https://doi.org/10.2147/IJN.S249511 PMid:32801694 PMCid:PMC7395705
38. Seo YG, Kim DW, Yeo WH, Ramasamy T, Oh YK, Park YJ, et al. Docetaxel-Loaded Thermosensitive and Bioadhesive Nanomicelles as a Rectal Drug Delivery System for Enhanced Chemotherapeutic Effect. Pharm Res. 2013 Jul;307:1860-70. https://doi.org/10.1007/s11095-013-1029-0 PMid:23549753
39. Beheshtizadeh N, Amiri Z, Tabatabaei SZ, Seraji AA, Gharibshahian M, Nadi A, et al. Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches. J Transl Med. 2024 May 30;221:520. https://doi.org/10.1186/s12967-024-05347-9 PMid:38816723 PMCid:PMC11137998
40. Huang A, Zhou W, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China, Changsha Medical University, Academician Workstation, Changsha 410219, China. Mn-based cGAS-STING activation for tumor therapy. Chin J Cancer Res. 2023;351:19-43. https://doi.org/10.21147/j.issn.1000-9604.2023.01.04 PMid:36910853 PMCid:PMC9992997
41. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev. 2017 Jan;108:25-38. https://doi.org/10.1016/j.addr.2016.04.025 PMid:27137110
42. Nirmala MJ, Kizhuveetil U, Johnson A, G B, Nagarajan R, Muthuvijayan V. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead. RSC Adv. 2023;1313:8606-29. https://doi.org/10.1039/D2RA07863E PMid:36926304 PMCid:PMC10013677
43. Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C. 2019 May;98:1252-76. https://doi.org/10.1016/j.msec.2019.01.066 PMid:30813007
44. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP. Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J Pers Med. 2021 Jun 18;116:571. https://doi.org/10.3390/jpm11060571 PMid:34207137 PMCid:PMC8234032
45. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020 Aug 20;7:193. https://doi.org/10.3389/fmolb.2020.00193 PMid:32974385 PMCid:PMC7468194
46. Sekino Y, Teishima J. Molecular mechanisms of docetaxel resistance in prostate cancer. Cancer Drug Resist [Internet]. 2020 [cited 2024 Jun 21]; Available from: https://www.oaepublish.com/articles/cdr.2020.37 https://doi.org/10.20517/cdr.2020.37 PMid:35582222 PMCid:PMC8992564
47. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes. 2007; https://doi.org/10.1002/chin.200739258
48. Sun X, Zhao P, Lin J, Chen K, Shen J. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system. Cancer Drug Resist. 2023;62:390-415. https://doi.org/10.20517/cdr.2023.16 PMid:37457134 PMCid:PMC10344729
49. Behzadi S, Serpooshan V, Tao W, Hamaly MA, Alkawareek MY, Dreaden EC, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev. 2017;4614:4218-44. https://doi.org/10.1039/C6CS00636A PMid:28585944 PMCid:PMC5593313
50. Xiao X, Teng F, Shi C, Chen J, Wu S, Wang B, et al. Polymeric nanoparticles-Promising carriers for cancer therapy. Front Bioeng Biotechnol. 2022 Oct 7;10:1024143. https://doi.org/10.3389/fbioe.2022.1024143 PMid:36277396 PMCid:PMC9585261
51. Feczkó T. Polymeric nanotherapeutics acting at special regions of body. J Drug Deliv Sci Technol. 2021 Aug;64:102597. https://doi.org/10.1016/j.jddst.2021.102597
52. Zhang N, Wang, Li. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Nanomedicine. 2012 Jun;3281. https://doi.org/10.2147/IJN.S32520 PMid:22802688 PMCid:PMC3396388
53. Ruiz-Gatón L, Espuelas S, Larrañeta E, Reviakine I, Yate LA, Irache JM. Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel. Eur J Pharm Sci. 2018 Jun;118:165-75. https://doi.org/10.1016/j.ejps.2018.03.028 PMid:29597043
54. Gao H, Zhang S, Yang Z, Cao S, Jiang X, Pang Z. In vitro and in vivo intracellular distribution and anti-glioblastoma effects of docetaxel-loaded nanoparticles functioned with IL-13 peptide. Int J Pharm. 2014 May;466(1-2):8-17. https://doi.org/10.1016/j.ijpharm.2014.03.012 PMid:24607217
55. Kushwah V, Katiyar SS, Agrawal AK, Gupta RC, Jain S. Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy. Nanomedicine Nanotechnol Biol Med. 2018 Jul;145:1629-41. https://doi.org/10.1016/j.nano.2018.04.009 PMid:29684527
56. Chu KS, Schorzman AN, Finniss MC, Bowerman CJ, Peng L, Luft JC, et al. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials. 2013 Nov;3433:8424-9. https://doi.org/10.1016/j.biomaterials.2013.07.038 PMid:23899444 PMCid:PMC3807740
57. Zhang Z, Yu, Tan, Zhuang, Song, Wang, et al. Antitumor activity of docetaxel-loaded polymeric nanoparticles fabricated by Shirasu porous glass membrane-emulsification technique. Int J Nanomedicine. 2013 Jul;2641. https://doi.org/10.2147/IJN.S48214 PMid:23935362 PMCid:PMC3735276
58. Sachdeva B, Sachdeva P, Negi A, Ghosh S, Han S, Dewanjee S, et al. Chitosan Nanoparticles-Based Cancer Drug Delivery: Application and Challenges. Mar Drugs. 2023 Mar 28;214:211. https://doi.org/10.3390/md21040211 PMid:37103352 PMCid:PMC10142570
59. Hosseini M, Amiri M, Ghanbari M, Mahdi MA, Abdulsahib WK, Salavati-Niasari M. Drug delivery based on chitosan, β-cyclodextrin and sodium carboxymethyl cellulose as well as nanocarriers for advanced leukemia treatment. Biomed Pharmacother. 2022 Sep;153:113369. https://doi.org/10.1016/j.biopha.2022.113369 PMid:35780615
60. Li X, Liu J, Qiu N. Cyclodextrin-Based Polymeric Drug Delivery Systems for Cancer Therapy. Polymers. 2023 Mar 11;156:1400. https://doi.org/10.3390/polym15061400 PMid:36987181 PMCid:PMC10052104
61. Saremi S, Dinarvand R, Kebriaeezadeh A, Ostad SN, Atyabi F. Enhanced Oral Delivery of Docetaxel Using Thiolated Chitosan Nanoparticles: Preparation, In Vitro and In Vivo Studies. BioMed Res Int. 2013;2013:1-8. https://doi.org/10.1155/2013/150478 PMid:23971023 PMCid:PMC3736506
62. Ahmad N, Alam MA, Ahmad R, Naqvi AA, Ahmad FJ. RETRACTED ARTICLE: Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer. Artif Cells Nanomedicine Biotechnol. 2018 Feb 17;462:432-46. https://doi.org/10.1080/21691401.2017.1324466 PMid:28503995
63. Badran MM, Alomrani AH, Harisa GI, Ashour AE, Kumar A, Yassin AE. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability. Biomed Pharmacother. 2018 Oct;106:1461-8. https://doi.org/10.1016/j.biopha.2018.07.102 PMid:30119220
64. Gallego-Yerga L, Posadas I, De La Torre C, Ruiz-Almansa J, Sansone F, Ortiz Mellet C, et al. Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells. Front Pharmacol. 2017 May 8;8:249. https://doi.org/10.3389/fphar.2017.00249 PMid:28533751 PMCid:PMC5420566
65. Mazzaferro S, Bouchemal K, Skanji R, Gueutin C, Chacun H, Ponchel G. Intestinal permeation enhancement of docetaxel encapsulated into methyl-β-cyclodextrin/poly(isobutylcyanoacrylate) nanoparticles coated with thiolated chitosan. J Controlled Release. 2012 Sep;1623:568-74. https://doi.org/10.1016/j.jconrel.2012.08.005 PMid:22902592
66. Liu T, Xue W, Ke B, Xie MQ, Ma D. Star-shaped cyclodextrin-poly(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy. Biomaterials. 2014 Apr;3512:3865-72. https://doi.org/10.1016/j.biomaterials.2014.01.040 PMid:24486215
67. Tao J, Xu J, Chen F, Xu B, Gao J, Hu Y. Folate acid-Cyclodextrin/Docetaxel induces apoptosis in KB cells via the intrinsic mitochondrial pathway and displays antitumor activity in vivo. Eur J Pharm Sci. 2018 Jan;111:540-8. https://doi.org/10.1016/j.ejps.2017.10.039 PMid:29097305
68. Kim DD, Cho HJ, Park JW, Yoon IS. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomedicine. 2014 Jan;495. https://doi.org/10.2147/IJN.S56648 PMid:24531717 PMCid:PMC3894956
69. Alven S, Nqoro X, Buyana B, Aderibigbe BA. Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer. Pharmaceutics. 2020 Apr 29;125:406. https://doi.org/10.3390/pharmaceutics12050406 PMid:32365495 PMCid:PMC7284459
70. Murakami M, Ernsting MJ, Undzys E, Holwell N, Foltz WD, Li SD. Docetaxel Conjugate Nanoparticles That Target α-Smooth Muscle Actin-Expressing Stromal Cells Suppress Breast Cancer Metastasis. Cancer Res. 2013 Aug 1;7315:4862-71. https://doi.org/10.1158/0008-5472.CAN-13-0062 PMid:23907638
71. Kulhari H, Pooja D, Shrivastava S, V.G.M N, Sistla R. Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. Colloids Surf B Biointerfaces. 2014 May;117:166-73. https://doi.org/10.1016/j.colsurfb.2014.02.026 PMid:24632389
72. Haider MS, Lübtow MM, Endres S, Forster S, Flegler VJ, Böttcher B, et al. Think Beyond the Core: Impact of the Hydrophilic Corona on Drug Solubilization Using Polymer Micelles. ACS Appl Mater Interfaces. 2020 Jun 3;1222:24531-43. https://doi.org/10.1021/acsami.9b22495 PMid:32378873
73. Zhang Y, Huang Y, Li S. Polymeric Micelles: Nanocarriers for Cancer-Targeted Drug Delivery. AAPS PharmSciTech. 2014 Aug;154:862-71. https://doi.org/10.1208/s12249-014-0113-z PMid:24700296 PMCid:PMC4113619
74. Wang Y, Chen L, Tan L, Zhao Q, Luo F, Wei Y, et al. PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy. Biomaterials. 2014 Aug;3525:6972-85. https://doi.org/10.1016/j.biomaterials.2014.04.099 PMid:24836952
75. Varshosaz J, Enteshari S, Hassanzadeh F, Hashemi-Beni B, Minaiyan M, Mirsafaei R. Synthesis, in vitro characterization, and anti-tumor effects of novel polystyrene-poly(amide-ether-ester-imide) co-polymeric micelles for delivery of docetaxel in breast cancer in Balb/C mice. Drug Dev Ind Pharm. 2018 Jul 3;447:1139-57. https://doi.org/10.1080/03639045.2018.1438462 PMid:29436875
76. Dou J, Zhang H, Liu X, Zhang M, Zhai G. Preparation and evaluation in vitro and in vivo of docetaxel loaded mixed micelles for oral administration. Colloids Surf B Biointerfaces. 2014 Feb;114:20-7. https://doi.org/10.1016/j.colsurfb.2013.09.010 PMid:24157590
77. Guo X, Zhao Z, Chen D, Qiao M, Wan F, Cun D, et al. Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors. Asian J Pharm Sci. 2019 Jan;141:78-85. https://doi.org/10.1016/j.ajps.2018.03.002 PMid:32104440 PMCid:PMC7032195
78. Guan Q, Sun D, Zhang G, Sun C, Wang M, Ji D, et al. Docetaxel-Loaded Self-Assembly Stearic Acid-Modified Bletilla striata Polysaccharide Micelles and Their Anticancer Effect: Preparation, Characterization, Cellular Uptake and In Vitro Evaluation. Molecules. 2016 Dec 2;2112:1641. https://doi.org/10.3390/molecules21121641 PMid:27918445 PMCid:PMC6273633
79. Hekmat A, Attar H, Seyf Kordi A, Iman M, Jaafari M. New Oral Formulation and in Vitro Evaluation of Docetaxel-Loaded Nanomicelles. Molecules. 2016 Sep 21;219:1265. https://doi.org/10.3390/molecules21091265 PMid:27657038 PMCid:PMC6274371
80. Song CK, Yoon IS, Kim DD. Poloxamer-based solid dispersions for oral delivery of docetaxel: Differential effects of F68 and P85 on oral docetaxel bioavailability. Int J Pharm. 2016 Jun;507(1-2):102-108. https://doi.org/10.1016/j.ijpharm.2016.05.002 PMid:27154250
81. Zhao J, Mi Y, Feng SS. Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials. 2013 Apr;3413:3411-3421. https://doi.org/10.1016/j.biomaterials.2013.01.009 PMid:23375951
82. Lang T, Dong X, Zheng Z, Liu Y, Wang G, Yin Q, et al. Tumor microenvironment-responsive docetaxel-loaded micelle combats metastatic breast cancer. Sci Bull. 2019 Jan;642:91-100. https://doi.org/10.1016/j.scib.2018.12.025 PMid:36659642
83. Raza K, Kumar N, Misra C, Kaushik L, Guru SK, Kumar P, et al. Dextran-PLGA-loaded docetaxel micelles with enhanced cytotoxicity and better pharmacokinetic profile. Int J Biol Macromol. 2016 Jul;88:206-12. https://doi.org/10.1016/j.ijbiomac.2016.03.064 PMid:27037052
84. Guo Y, He W, Yang S, Zhao D, Li Z, Luan Y. Co-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancer. Colloids Surf B Biointerfaces. 2017 Mar;151:119-27. https://doi.org/10.1016/j.colsurfb.2016.12.012 PMid:27988472
85. Wu J, Zhang H, Hu X, Liu R, Jiang W, Li Z, et al. Reduction-sensitive mixed micelles assembled from amphiphilic prodrugs for self-codelivery of DOX and DTX with synergistic cancer therapy. Colloids Surf B Biointerfaces. 2018 Jan;161:449-56. https://doi.org/10.1016/j.colsurfb.2017.11.011 PMid:29127937
86. Li W, Peng J, Yang Q, Chen L, Zhang L, Chen X, et al. α-Lipoic acid stabilized DTX/IR780 micelles for photoacoustic/fluorescence imaging guided photothermal therapy/chemotherapy of breast cancer. Biomater Sci. 2018;65:1201-16. https://doi.org/10.1039/C8BM00096D PMid:29578215
87. Raju A, Muthu MS, Feng SS. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv. 2013 Jun;106:747-60. https://doi.org/10.1517/17425247.2013.777425 PMid:23458409
88. Khodaverdi E, Tayarani-Najaran Z, Minbashi E, Alibolandi M, Hosseini J, Sepahi S, et al. Docetaxel-Loaded Mixed Micelles and Polymersomes Composed of Poly (caprolactone)-Poly (ethylene glycol) (PEG-PCL) and Poly (lactic acid)-Poly (ethylene glycol) (PEG-PLA): Preparation and In-vitro Characterization.
89. Tao W, Zeng X, Liu T, Wang Z, Xiong Q, Ouyang C, et al. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy. Acta Biomater. 2013 Nov;911:8910-20. https://doi.org/10.1016/j.actbio.2013.06.034 PMid:23816645
90. Mikhail AS, Allen C. Poly(ethylene glycol)- b -poly(ε-caprolactone) Micelles Containing Chemically Conjugated and Physically Entrapped Docetaxel: Synthesis, Characterization, and the Influence of the Drug on Micelle Morphology. Biomacromolecules. 2010 May 10;115:1273-80. https://doi.org/10.1021/bm100073s PMid:20369884
91. Liu Y, Li K, Pan J, Liu B, Feng SS. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials. 2010 Jan;312:330-8. https://doi.org/10.1016/j.biomaterials.2009.09.036 PMid:19783040
92. Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, et al. A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment. Nanoscale Res Lett. 2009 Dec;412:1530. https://doi.org/10.1007/s11671-009-9431-6 PMid:20652101 PMCid:PMC2894322
93. Koopaei MN, Khoshayand MR, Mostafavi SH, Amini M, Khorramizadeh MR, Tehrani MJ, et al. Docetaxel Loaded PEG-PLGA Nanoparticles: Optimized Drug Loading, In-vitro Cytotoxicity and In-vivo Antitumor Effect. 2014;
94. Quaglia F, Ostacolo L, Mazzaglia A, Villari V, Zaccaria D, Sciortino MT. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials. 2009 Jan;303:374-82. https://doi.org/10.1016/j.biomaterials.2008.09.035 PMid:18930312
95. Etrych T, Šírová M, Starovoytova L, Říhová B, Ulbrich K. HPMA Copolymer Conjugates of Paclitaxel and Docetaxel with pH-Controlled Drug Release. Mol Pharm. 2010 Aug 2;74:1015-26. https://doi.org/10.1021/mp100119f PMid:20518512
96. Jain A, Thakur K, Kush P, Jain UK. Docetaxel loaded chitosan nanoparticles: Formulation, characterization and cytotoxicity studies. Int J Biol Macromol. 2014 Aug;69:546-53. https://doi.org/10.1016/j.ijbiomac.2014.06.029 PMid:24971551
97. Jiang W, Wang J, Yang L, Jiang X, Bai Z, Wang Z, et al. Nanostructured lipid carriers modified with PEGylated carboxymethylcellulose polymers for effective delivery of docetaxel. RSC Adv. 2015;5110:90386-95. https://doi.org/10.1039/C5RA13642C
98. Song S, Chen F, Qi H, Li F, Xin T, Xu J, et al. Multifunctional Tumor-Targeting Nanocarriers Based on Hyaluronic Acid-Mediated and pH-Sensitive Properties for Efficient Delivery of Docetaxel. Pharm Res. 2014 Apr;314:1032-45. https://doi.org/10.1007/s11095-013-1225-y PMid:24154802
99. Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Controlled Release. 2008 May;1281:23-31. https://doi.org/10.1016/j.jconrel.2008.02.003 PMid:18374444
100. Atyabi F, Saremi S, Akhlaghi SP, Dinarvand R, Ostad SN. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. Int J Nanomedicine. 2011 Jan;119. https://doi.org/10.2147/IJN.S15500 PMid:21289989 PMCid:PMC3026577
101. Mi Y, Liu Y, Feng SS. Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles for targeted and synergistic chemotherapy. Biomaterials. 2011 Jun;3216:4058-66. https://doi.org/10.1016/j.biomaterials.2011.02.022 PMid:21396707
102. Mu CF, Balakrishnan P, Cui FD, Yin YM, Lee YB, Choi HG, et al. The effects of mixed MPEG-PLA/Pluronic® copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials. 2010 Mar;318:2371-9. https://doi.org/10.1016/j.biomaterials.2009.11.102 PMid:20031202
103. Zhang Y, Wang X, Wang J, Zhang X, Zhang Q. Octreotide-Modified Polymeric Micelles as Potential Carriers for Targeted Docetaxel Delivery to Somatostatin Receptor Overexpressing Tumor Cells. Pharm Res. 2011 May;285:1167-78. https://doi.org/10.1007/s11095-011-0381-1 PMid:21340573
104. Liu B, Yang M, Li R, Ding Y, Qian X, Yu L, et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm. 2008 Jun;692:527-34. https://doi.org/10.1016/j.ejpb.2008.01.015 PMid:18359617
105. Miraj S, Saeed H, Iqtedar M, Albekairi NA, Ahmed N, Danish MZ, et al. Docetaxel-Loaded Methoxy poly(ethylene glycol)-poly (L-lactic Acid) Nanoparticles for Breast Cancer: Synthesis, Characterization, Method Validation, and Cytotoxicity. Pharmaceuticals. 2023 Nov 13;1611:1600. https://doi.org/10.3390/ph16111600 PMid:38004465 PMCid:PMC10675362
106. Li N, Mai Y, Liu Q, Gou G, Yang J. Docetaxel-loaded D-α-tocopheryl polyethylene glycol-1000 succinate liposomes improve lung cancer chemotherapy and reverse multidrug resistance. Drug Deliv Transl Res. 2021 Feb;111:131-41. https://doi.org/10.1007/s13346-020-00720-9 PMid:32052357
107. Maeyouf K, Sakpakdeejaroen I, Somani S, Meewan J, Ali-Jerman H, Laskar P, et al. Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells. Pharmaceutics. 2023 Nov 20;1511:2643. https://doi.org/10.3390/pharmaceutics15112643 PMid:38004621 PMCid:PMC10675605
108. Li N, Fu T, Fei W, Han T, Gu X, Hou Y, et al. Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells. J Pharm Pharmacol. 2019 Jul 3;718:1243-54. https://doi.org/10.1111/jphp.13126 PMid:31215039
109. Zhao X, Zhao Y, Geng L, Li X, Wang X, Liu Z, et al. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: Evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. J Chromatogr B. 2011 Dec;87931:3721-7. https://doi.org/10.1016/j.jchromb.2011.10.015 PMid:22035980
110. Yuan Z, Chen D, Zhang S, Zheng Z. Preparation, Characterization and Evaluation of Docetaxel-loaded, Folate-conjugated PEG-liposomes. YAKUGAKU ZASSHI. 2010 Oct 1;13010:1353-9. https://doi.org/10.1248/yakushi.130.1353 PMid:20930488
111. Zhu X, Huang S, Li L, Wang S, Chen J, Guan Y, et al. Glycyrrhetinic acid-decorated and docetaxel-loaded thermosensitive liposomes for combination therapy against hepatocellular carcinoma. J Nanoparticle Res. 2021 Aug;238:158. https://doi.org/10.1007/s11051-021-05273-7
112. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, et al. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J Controlled Release. 2009 Dec;1402:86-94. https://doi.org/10.1016/j.jconrel.2009.08.015 PMid:19709639
113. Gao K, Sun J, Liu K, Liu X, He Z. Preparation and Characterization of a Submicron Lipid Emulsion of Docetaxel: Submicron Lipid Emulsion of Docetaxel. Drug Dev Ind Pharm. 2008 Jan;3411:1227-37. https://doi.org/10.1080/03639040802005057 PMid:18720137
114. Wu Y, Wang M, Li Y, Xia H, Cheng Y, Liu C, et al. The Fabrication of Docetaxel-Containing Emulsion for Drug Release Kinetics and Lipid Peroxidation. Pharmaceutics. 2022 Sep 21;1410:1993. https://doi.org/10.3390/pharmaceutics14101993 PMid:36297429 PMCid:PMC9607308
115. Gaoe H, Pang Z, Pan S, Cao S, Yang Z, Chen C, et al. Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharm Res. 2012 Feb;352:333-41. https://doi.org/10.1007/s12272-012-0214-8 PMid:22370788
116. Chen Y, Chen C, Zheng J, Chen Z, Shi Q, Liu H. Development of a Solid Supersaturatable Self-Emulsifying Drug Delivery System of Docetaxel with Improved Dissolution and Bioavailability. Biol Pharm Bull. 2011;342:278-86. https://doi.org/10.1248/bpb.34.278 PMid:21415541
117. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009 Jan;302:226-32. https://doi.org/10.1016/j.biomaterials.2008.09.014 PMid:18851881
118. Pawar H, Surapaneni SK, Tikoo K, Singh C, Burman R, Gill MS, et al. Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: In vitro evaluation, pharmacokinetic and biodistribution in rats. Drug Deliv. 2016 May 3;234:1453-68. https://doi.org/10.3109/10717544.2016.1138339 PMid:26878325
119. Sun B, Luo C, Li L, Wang M, Du Y, Di D, et al. Core-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxel. Colloids Surf B Biointerfaces. 2016 Jul;143:47-55. https://doi.org/10.1016/j.colsurfb.2016.02.065 PMid:27011346
120. Fang G, Tang B, Chao Y, Xu H, Gou J, Zhang Y, et al. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study. Mol Pharm. 2015 Jul 6;127:2384-95. https://doi.org/10.1021/acs.molpharmaceut.5b00081 PMid:25974386
121. Fan X, Chen J, Shen Q. Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery. Int J Pharm. 2013 Dec;4582:296-304. https://doi.org/10.1016/j.ijpharm.2013.10.036 PMid:24177313
122. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013 Dec;81:102. https://doi.org/10.1186/1556-276X-8-102 PMid:23432972 PMCid:PMC3599573
123. Deeken JF, Slack R, Weiss GJ, Ramanathan RK, Pishvaian MJ, Hwang J, et al. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2013 Mar;713:627-33. https://doi.org/10.1007/s00280-012-2048-y PMid:23274395 PMCid:PMC3703246
124. Fan Y, Wang Q, Lin G, Shi Y, Gu Z, Ding T. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. Acta Biomater. 2017 Oct;62:257-72. https://doi.org/10.1016/j.actbio.2017.08.034 PMid:28859899
125. Kushwah V, Jain DK, Agrawal AK, Jain S. Improved antitumor efficacy and reduced toxicity of docetaxel using anacardic acid functionalized stealth liposomes. Colloids Surf B Biointerfaces. 2018 Dec;172:213-23. https://doi.org/10.1016/j.colsurfb.2018.08.047 PMid:30172202
126. Radha G, Rani Ts, Sarvani B. A review on proniosomal drug delivery system for targeted drug action. J Basic Clin Pharm. 2013;42:42. https://doi.org/10.4103/0976-0105.113609 PMid:24808669 PMCid:PMC3979263
127. Khatoon M, Shah KU, Din FU, Shah SU, Rehman AU, Dilawar N, et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv. 2017 Nov;242:56-69. https://doi.org/10.1080/10717544.2017.1384520 PMid:29130758 PMCid:PMC8812579
128. Liu H, Tu L, Zhou Y, Dang Z, Wang L, Du J, et al. Improved Bioavailability and Antitumor Effect of Docetaxel by TPGS Modified Proniosomes: In Vitro and In Vivo Evaluations. Sci Rep. 2017 Mar 7;71:43372. https://doi.org/10.1038/srep43372 PMid:28266539 PMCid:PMC5339906
129. Zhang T, Li M, Yang R, Zhang D, Guan J, Yu J, et al. Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer. Int J Pharm. 2018 Jul;546(1-2):61-9. https://doi.org/10.1016/j.ijpharm.2018.05.032 PMid:29763687
130. Pan W, Ma, Chen F, Ye, Dong, Xue, et al. Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): formulation and pharmacokinetics. Int J Nanomedicine. 2013 Oct;4045. https://doi.org/10.2147/IJN.S47956 PMid:24179332 PMCid:PMC3810894
131. Verma P, Meher JG, Asthana S, Pawar VK, Chaurasia M, Chourasia MK. Perspectives of nanoemulsion assisted oral delivery of docetaxel for improved chemotherapy of cancer. Drug Deliv. 2016 Feb 12;232:479-88. https://doi.org/10.3109/10717544.2014.920430 PMid:24901205
132. Pandey G, Mittapelly N, Valicherla GR, Shukla RP, Sharma S, Banala VT, et al. P-gp modulatory acetyl-11-keto-β-boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxel. Colloids Surf B Biointerfaces. 2017 Jul;155:276-86. https://doi.org/10.1016/j.colsurfb.2017.04.028 PMid:28437753
133. Seo YG, Kim DH, Ramasamy T, Kim JH, Marasini N, Oh YK, et al. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm. 2013 Aug;452(1-2):412-20. https://doi.org/10.1016/j.ijpharm.2013.05.034 PMid:23707964
134. Quan Q, Kim DW, Marasini N, Kim DH, Kim JK, Kim JO, et al. Physicochemical characterization and in vivo evaluation of solid self-nanoemulsifying drug delivery system for oral administration of docetaxel. J Microencapsul. 2013 Jun;304:307-14. https://doi.org/10.3109/02652048.2012.726280 PMid:23101936
135. German-Cortés J, Vilar-Hernández M, Rafael D, Abasolo I, Andrade F. Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment. Pharmaceutics. 2023 Mar 3;153:831. https://doi.org/10.3390/pharmaceutics15030831 PMid:36986692 PMCid:PMC10056426
136. Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B. Docetaxel-Loaded Solid Lipid Nanoparticles: Preparation, Characterization, In Vitro, and In Vivo Evaluations. J Pharm Sci. 2013 Jun;1026:1994-2004. https://doi.org/10.1002/jps.23522 PMid:23558514
137. Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO, Cui Z. Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and in Vivo Evaluation. Mol Pharm. 2014 Apr 7;114:1239-49. https://doi.org/10.1021/mp4006968 PMid:24621456 PMCid:PMC3993949
138. Zhu X, Huang S, Xie Y, Zhang H, Hou L, Zhang Y, et al. Folic acid mediated solid lipid nanocarriers loaded with docetaxel and oxidized single-walled carbon nanotubes. J Nanoparticle Res. 2014 Jan;161:2207. https://doi.org/10.1007/s11051-013-2207-z
139. Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery. Adv Pharm Bull. 2020 Feb 18;102:150-65. https://doi.org/10.34172/apb.2020.021 PMid:32373485 PMCid:PMC7191226
140. Joseph T, Kar Mahapatra D, Esmaeili A, Piszczyk Ł, Hasanin M, Kattali M, et al. Nanoparticles: Taking a Unique Position in Medicine. Nanomaterials. 2023 Jan 31;133:574. https://doi.org/10.3390/nano13030574 PMid:36770535 PMCid:PMC9920911
141. Hammami I, Alabdallah NM, Jomaa AA, Kamoun M. Gold nanoparticles: Synthesis properties and applications. J King Saud Univ - Sci. 2021 Oct;337:101560. https://doi.org/10.1016/j.jksus.2021.101560 142. Kong FY, Zhang JW, Li RF, Wang ZX, Wang WJ, Wang W. Unique Roles of Gold Nanoparticles in Drug Delivery, Targeting and Imaging Applications. Molecules. 2017 Aug 31;229:1445. https://doi.org/10.3390/molecules22091445 PMid:28858253 PMCid:PMC6151763
143. François A, Laroche A, Pinaud N, Salmon L, Ruiz J, Robert J, et al. Encapsulation of Docetaxel into PEGylated Gold Nanoparticles for Vectorization to Cancer Cells. ChemMedChem. 2011 Nov 4;611:2003-8. https://doi.org/10.1002/cmdc.201100311 PMid:21834092
144. Wan J, Ma X, Xu D, Yang B, Yang S, Han S. Docetaxel-decorated anticancer drug and gold nanoparticles encapsulated apatite carrier for the treatment of liver cancer. J Photochem Photobiol B. 2018 Aug;185:73-9. https://doi.org/10.1016/j.jphotobiol.2018.05.021 PMid:29870961
145. Bharti C, Gulati N, Nagaich U, Pal A. Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharm Investig. 2015;53:124. https://doi.org/10.4103/2230-973X.160844 PMid:26258053 PMCid:PMC4522861
146. Li L, Tang F, Liu H, Liu T, Hao N, Chen D, et al. In Vivo Delivery of Silica Nanorattle Encapsulated Docetaxel for Liver Cancer Therapy with Low Toxicity and High Efficacy. ACS Nano. 2010 Nov 23;411:6874-82. https://doi.org/10.1021/nn100918a PMid:20973487
147. Khosraviyan P, Shafiee Ardestani M, Khoobi M, Ostad SN, Dorkoosh FA, Akbari Javar H, et al. Mesoporous silica nanoparticles functionalized with folic acid/methionine for active targeted delivery of docetaxel. OncoTargets Ther. 2016 Dec;Volume 9:7315-30. https://doi.org/10.2147/OTT.S113815 PMid:27980423 PMCid:PMC5144897
148. Wang L, Zhang, Zhang, Shi, Zhang, Zhang Z, et al. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int J Nanomedicine. 2011 Oct;2641. https://doi.org/10.2147/IJN.S24167 PMid:22114495 PMCid:PMC3218578
149. Arora S, Saharan R, Kaur H, Kaur I, Bubber P, Bharadwaj LM. Attachment of Docetaxel to Multiwalled Carbon Nanotubes for Drug Delivery Applications. Adv Sci Lett. 2012 Oct 1;171:70-5. https://doi.org/10.1166/asl.2012.4251
150. Shi J, Zhang H, Wang L, Li L, Wang H, Wang Z, et al. PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor. Biomaterials. 2013 Jan;341:251-61. https://doi.org/10.1016/j.biomaterials.2012.09.039 PMid:23069706
151. Raza K, Thotakura N, Kumar P, Joshi M, Bhushan S, Bhatia A, et al. C 60 -fullerenes for delivery of docetaxel to breast cancer cells: A promising approach for enhanced efficacy and better pharmacokinetic profile. Int J Pharm. 2015 Nov;4951:551-9. https://doi.org/10.1016/j.ijpharm.2015.09.016 PMid:26383841
152. Rezaei M, Abbasi A, Varshochian R, Dinarvand R, Jeddi-Tehrani M. NanoMIL-100(Fe) containing docetaxel for breast cancer therapy. Artif Cells Nanomedicine Biotechnol. 2018 Oct 3;467:1390-401. https://doi.org/10.1080/21691401.2017.1369425 PMid:28838252
153. Parajapati S, Maurya S, Das M, Tilak VK, Verma KK, Dhakar RC. Potential Application of Dendrimers in Drug Delivery: A Concise Review and Update. Journal of Drug Delivery and Therapeutics. 2016;6(2):71-88 . https://doi.org/10.22270/jddt.v6i2.1195
154. Le NTT, Nguyen TNQ, Cao VD, Hoang DT, Ngo VC, Hoang Thi TT. Recent Progress and Advances of Multi-Stimuli-Responsive Dendrimers in Drug Delivery for Cancer Treatment. Pharmaceutics. 2019 Nov 8;1111:591. https://doi.org/10.3390/pharmaceutics11110591 PMid:31717376 PMCid:PMC6920789
155. Rai DB, Medicherla K, Pooja D, Kulhari H. Dendrimer-Mediated Delivery of Anticancer Drugs for Colon Cancer Treatment. Pharmaceutics. 2023 Mar 1;153:801. https://doi.org/10.3390/pharmaceutics15030801 PMid:36986662 PMCid:PMC10059812
156. Benito JM, Gómez-García M, Ortiz Mellet C, Baussanne I, Defaye J, García Fernández JM. Optimizing Saccharide-Directed Molecular Delivery to Biological Receptors: Design, Synthesis, and Biological Evaluation of Glycodendrimer−Cyclodextrin Conjugates. J Am Chem Soc. 2004 Aug 1;12633:10355-63. https://doi.org/10.1021/ja047864v PMid:15315450
157. Zhang N, Zhang. How nanotechnology can enhance docetaxel therapy. Int J Nanomedicine. 2013 Aug;2927. https://doi.org/10.2147/IJN.S46921 PMid:23950643 PMCid:PMC3742154
158. Gajbhiye V, Jain NK. The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials. 2011 Sep;3226:6213-25. https://doi.org/10.1016/j.biomaterials.2011.04.057 PMid:21616528
159. Pooja D, Kulhari H, Singh MK, Mukherjee S, Rachamalla SS, Sistla R. Dendrimer-TPGS mixed micelles for enhanced solubility and cellular toxicity of taxanes. Colloids Surf B Biointerfaces. 2014 Sep;121:461-8. https://doi.org/10.1016/j.colsurfb.2014.06.059 PMid:25063311
160. Kim TE, Chang JE. Recent Studies in Photodynamic Therapy for Cancer Treatment: From Basic Research to Clinical Trials. Pharmaceutics. 2023 Aug 31;159:2257. https://doi.org/10.3390/pharmaceutics15092257 PMid:37765226 PMCid:PMC10535460
161. Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Molecules. 2021 Nov 4;2621:6677. https://doi.org/10.3390/molecules26216677 PMid:34771085 PMCid:PMC8587155
162. Ho M, Mackey J. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014 May;253. https://doi.org/10.2147/CMAR.S40601 PMid:24904223 PMCid:PMC4041377
163. Rafiei P, Haddadi A. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine. 2017 Jan;Volume 12:935-47. https://doi.org/10.2147/IJN.S121881 PMid:28184163 PMCid:PMC5291330
164. Schwartzberg LS, Navari RM. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018 Jun;356:754-67. https://doi.org/10.1007/s12325-018-0707-z PMid:29796927 PMCid:PMC6015121
165. Guo L, Qin X, Xue L, Yang JY, Zhang Y, Zhu S, et al. A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents. Front Pharmacol. 2022 Aug 24;13:964076. https://doi.org/10.3389/fphar.2022.964076 PMid:36091776 PMCid:PMC9449419
166. Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, et al. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Oct 1;410:1344. https://doi.org/10.1001/jamaoncol.2018.2168 PMid:29978216 PMCid:PMC6233779
167. Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, et al. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Jul 1;2213:3157-63. https://doi.org/10.1158/1078-0432.CCR-15-2548 PMid:26847057
168. Zhang E, Xing R, Liu S, Li P. Current advances in development of new docetaxel formulations. Expert Opin Drug Deliv. 2019 Mar 4;163:301-12. https://doi.org/10.1080/17425247.2019.1583644 PMid:30773947
169. Williams R. Discontinued in 2013: oncology drugs. Expert Opin Investig Drugs. 2015 Jan 2;241:95-110. https://doi.org/10.1517/13543784.2015.971154 PMid:25315907
170. Mahalingam D, Nemunaitis JJ, Malik L, Sarantopoulos J, Weitman S, Sankhala K, et al. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec;746:1241-50. https://doi.org/10.1007/s00280-014-2602-x PMid:25304209
171. Ashford MB, England RM, Akhtar N. Highway to Success-Developing Advanced Polymer Therapeutics. Adv Ther. 2021 May;45:2000285. https://doi.org/10.1002/adtp.202000285
172. Zhang Y, Zhang W, Wang Y, Zhu J, Zhou M, Peng C, et al. Emerging nanotaxanes for cancer therapy. Biomaterials. 2021 May;272:120790. https://doi.org/10.1016/j.biomaterials.2021.120790 PMid:33836293
173. Atrafi F, Dumez H, Mathijssen RHJ, Menke Van Der Houven Van Oordt CW, Rijcken CJF, Hanssen R, et al. A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours. J Controlled Release. 2020 Sep;325:191-7. https://doi.org/10.1016/j.jconrel.2020.06.020 PMid:32590047
174. Piha-Paul SA, Thein KZ, De Souza P, Kefford R, Gangadhar T, Smith C, et al. First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Invest New Drugs. 2021 Aug;394:1047-56. https://doi.org/10.1007/s10637-021-01081-x PMid:33594602
175. Mignani S, Shi X, Rodrigues J, Tomas H, Karpus A, Majoral JP. First-in-class and best-in-class dendrimer nanoplatforms from concept to clinic: Lessons learned moving forward. Eur J Med Chem. 2021 Jul;219:113456. https://doi.org/10.1016/j.ejmech.2021.113456 PMid:33878563
176. Zheng X, Xie J, Zhang X, Sun W, Zhao H, Li Y, et al. An overview of polymeric nanomicelles in clinical trials and on the market. Chin Chem Lett. 2021 Jan;321:243-57. https://doi.org/10.1016/j.cclet.2020.11.029
177. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016 Mar;11:10-29. https://doi.org/10.1002/btm2.10003 PMid:29313004 PMCid:PMC5689513
178. Song SY, Kim K pyo, Jeong SY, Park J, Park J, Jung J, et al. Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer model. Oncotarget. 2016 Nov 22;747:77348-57. https://doi.org/10.18632/oncotarget.12668 PMid:27764799 PMCid:PMC5363590
179. Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M. Targeting EphA2 in cancer. J Hematol OncolJ Hematol Oncol. 2020 Dec;131:114. https://doi.org/10.1186/s13045-020-00944-9 PMid:32811512 PMCid:PMC7433191
180. Dahan A, Markovic M, Aponick A, Zimmermann EM, Ben-Shabat S. The Prospects of Lipidic Prodrugs: An Old Approach with an Emerging Future. Future Med Chem. 2019 Oct;1119:2563-71. https://doi.org/10.4155/fmc-2019-0155 PMid:31633401
181. Ahmad A, Sheikh S, Taran R, Srivastav SP, Prasad K, Rajappa SJ, et al. Therapeutic Efficacy of a Novel Nanosomal Docetaxel Lipid Suspension Compared With Taxotere in Locally Advanced or Metastatic Breast Cancer Patients. Clin Breast Cancer. 2014 Jun;143:177-81. https://doi.org/10.1016/j.clbc.2013.09.011 PMid:24287370
182. Subramanian S, Prasanna R, Biswas G, Das Majumdar SK, Joshi N, Bunger D, et al. Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study. Breast Cancer Targets Ther. 2020 May;Volume 12:77-85. https://doi.org/10.2147/BCTT.S236108 PMid:32547188 PMCid:PMC7250303
183. McKeage K. Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer. Clin Drug Investig. 2017 Apr;374:405-10. https://doi.org/10.1007/s40261-017-0510-7 PMid:28255844
184. Badiginchala R, Dattatreya PS, Suresh AVS, Nirni SS, Andra VV, Bunger D, et al. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer. OncoTargets Ther. 2023 Apr;Volume 16:215-25. https://doi.org/10.2147/OTT.S400824 PMid:37033671 PMCid:PMC10075221
185. Pang X, Du HL, Zhang HQ, Zhai YJ, Zhai GX. Polymer-drug conjugates: present state of play and future perspectives. Drug Discov Today. 2013 Dec;18(23-24):1316-22. https://doi.org/10.1016/j.drudis.2013.09.007 PMid:24055841
186. Pirollo KF, Nemunaitis J, Leung PK, Nunan R, Adams J, Chang EH. Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Mol Ther. 2016 Sep;249:1697-706. https://doi.org/10.1038/mt.2016.135 PMid:27357628 PMCid:PMC5113104
187. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced‐stage nonsmall cell lung cancer: A multicenter phase 2 study. Cancer. 2008 Nov;1139:2512-7. https://doi.org/10.1002/cncr.23902 PMid:18816622
188. Lin Q. Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study. Oncol Lett [Internet]. 2012 Jan 19 [cited 2024 Jun 20]; Available from: http://www.spandidos-publications.com/10.3892/ol.2012.575 https://doi.org/10.3892/ol.2012.575 189. Rajappa S, Joshi A, Doval D, Batra U, Rajendranath R, Deo A, et al. [Experts' Opinion] Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Oncol Lett [Internet]. 2018 Jul 2 [cited 2024 Jun 9]; Available from: http://www.spandidos-publications.com/10.3892/ol.2018.9057 https://doi.org/10.3892/ol.2018.9057 PMid:30127986 PMCid:PMC6096158
190. Narang JK, Narang RS, Pandita D, Lather V, Dogra A. Nano-Oncologicals: Regulatory Aspects and Safety Issues. Appl Clin Res Clin Trials Regul Aff. 2018 Apr 6;52:122-31. https://doi.org/10.2174/2213476X05666180528094458
Published
Abstract Display: 146 
PDF Downloads: 138 PDF Downloads: 33 How to Cite
Issue
Section
Copyright (c) 2026 Omkar Kolhe , Mukesh Ratnaparkhi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.